Blab Business
IPG Photonics to Acquire Lumibird Medical for 300 Million, Expanding Medical Laser Platform
IPG Photonics, the fiber‑laser powerhouse listed on the Nasdaq, announced on July 16, 2026 that it has entered into a binding offer to buy France‑based Lumibird Medical for €300 million in cash. The deal is designed to broaden IPG’s Advanced Solutions portfolio and add a high‑margin business that the company says will be accretive to gross margin, EBITDA and adjusted earnings per share.
The purchase follows IPG’s strategy to deepen its presence in medical markets that are driven by non‑discretionary spending. Lumibird specializes in diagnostic and therapeutic laser systems for ophthalmology, tackling conditions such as cataracts, glaucoma, dry eye and age‑related macular degeneration. Its product line includes well‑known brands such as Quantel Medical, Ellex and Optotek Medical.
For the fiscal year ended December 31, 2025, Lumibird reported revenue of €112.2 million and EBITDA of €24.1 million, giving an EBITDA margin of 21.5 %. According to the press release, the purchase price will be paid in cash at closing, and a contingent earnout of up to €50 million will be paid if Lumibird meets specified performance targets in 2026 and 2027.
IPG will fund the acquisition with its cash on hand. CEO Dr. Mark Gitin said the combination would create a “scaled medical platform” that leverages complementary strengths in ophthalmology and urology.
Lumibird’s CEO, Jean‑Marc Gendre, welcomed the partnership, noting that integration with IPG would provide access to the company’s laser and photonics expertise while preserving its culture of innovation. Lumibird’s headquarters are in France, and the company operates three global facilities with more than 450 employees.
The transaction is expected to add roughly $1 billion in addressable market to IPG’s Advanced Solutions segment, according to the company. IPG has manufacturing facilities in the United States, Germany, Russia and Italy, and its laser products are used in materials processing, telecommunications and medical applications.
IPG and Lumibird are currently completing an information and consultation process with Lumibird’s works council in accordance with French law. The parties anticipate signing a definitive purchase agreement and expect the transaction to close in the fourth quarter of 2026, subject to customary closing conditions.
IPG will hold a conference call on July 17, 2026 at 8:00 a.m. ET to discuss the acquisition. The call will be available via telephone and webcast on the company’s investor relations website.
The acquisition represents a significant expansion of IPG’s medical laser capabilities. By combining Lumibird’s ophthalmology expertise with IPG’s established urology solutions, the company aims to accelerate innovation and broaden its commercial reach in medical markets that require high‑precision laser technology.
At present, the transaction remains subject to regulatory approvals, the completion of due diligence, and the satisfaction of customary closing conditions. IPG’s next earnings report will include a detailed assessment of the acquisition’s financial impact, and the company will provide further updates as the deal progresses.
The acquisition underscores the growing demand for medical laser solutions in regulated markets and reflects IPG’s broader strategy to consolidate its position as a global leader in fiber laser technology.
The purchase follows IPG’s strategy to deepen its presence in medical markets that are driven by non‑discretionary spending. Lumibird specializes in diagnostic and therapeutic laser systems for ophthalmology, tackling conditions such as cataracts, glaucoma, dry eye and age‑related macular degeneration. Its product line includes well‑known brands such as Quantel Medical, Ellex and Optotek Medical.
For the fiscal year ended December 31, 2025, Lumibird reported revenue of €112.2 million and EBITDA of €24.1 million, giving an EBITDA margin of 21.5 %. According to the press release, the purchase price will be paid in cash at closing, and a contingent earnout of up to €50 million will be paid if Lumibird meets specified performance targets in 2026 and 2027.
IPG will fund the acquisition with its cash on hand. CEO Dr. Mark Gitin said the combination would create a “scaled medical platform” that leverages complementary strengths in ophthalmology and urology.
Lumibird’s CEO, Jean‑Marc Gendre, welcomed the partnership, noting that integration with IPG would provide access to the company’s laser and photonics expertise while preserving its culture of innovation. Lumibird’s headquarters are in France, and the company operates three global facilities with more than 450 employees.
The transaction is expected to add roughly $1 billion in addressable market to IPG’s Advanced Solutions segment, according to the company. IPG has manufacturing facilities in the United States, Germany, Russia and Italy, and its laser products are used in materials processing, telecommunications and medical applications.
IPG and Lumibird are currently completing an information and consultation process with Lumibird’s works council in accordance with French law. The parties anticipate signing a definitive purchase agreement and expect the transaction to close in the fourth quarter of 2026, subject to customary closing conditions.
IPG will hold a conference call on July 17, 2026 at 8:00 a.m. ET to discuss the acquisition. The call will be available via telephone and webcast on the company’s investor relations website.
The acquisition represents a significant expansion of IPG’s medical laser capabilities. By combining Lumibird’s ophthalmology expertise with IPG’s established urology solutions, the company aims to accelerate innovation and broaden its commercial reach in medical markets that require high‑precision laser technology.
At present, the transaction remains subject to regulatory approvals, the completion of due diligence, and the satisfaction of customary closing conditions. IPG’s next earnings report will include a detailed assessment of the acquisition’s financial impact, and the company will provide further updates as the deal progresses.
The acquisition underscores the growing demand for medical laser solutions in regulated markets and reflects IPG’s broader strategy to consolidate its position as a global leader in fiber laser technology.
